These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32773446)

  • 1. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.
    Fabi SG; Cohen JL; Green LJ; Dhawan S; Kontis TC; Baumann L; Gross TM; Gallagher CJ; Brown J; Rubio RG
    Dermatol Surg; 2021 Jan; 47(1):48-54. PubMed ID: 32773446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials.
    Solish N; Burgess CM; Weinkle SH; Ablon G; Brown J; Kooken K; Rubio RG
    Aesthet Surg J; 2023 Feb; 43(2):205-214. PubMed ID: 36087303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.
    Green JB; Mariwalla K; Coleman K; Ablon G; Weinkle SH; Gallagher CJ; Vitarella D; Rubio RG
    Dermatol Surg; 2021 Jan; 47(1):42-46. PubMed ID: 32773447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
    Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
    J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
    Carruthers JD; Fagien S; Joseph JH; Humphrey SD; Biesman BS; Gallagher CJ; Liu Y; Rubio RG; ;
    Plast Reconstr Surg; 2020 Jan; 145(1):45-58. PubMed ID: 31609882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
    Solish N; Carruthers J; Kaufman J; Rubio RG; Gross TM; Gallagher CJ
    Drugs; 2021 Dec; 81(18):2091-2101. PubMed ID: 34787840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program.
    Cohen JL; Green LJ; Beer KR; Liu Y; Gallagher CJ
    Dermatol Surg; 2021 Apr; 47(4):511-515. PubMed ID: 33587381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
    Gallagher CJ; Bowsher RR; Clancy A; Dover JS; Humphrey S; Liu Y; Prawdzik G
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection.
    Glogau R; Kontis TC; Liu Y; Gallagher CJ
    Dermatol Surg; 2021 Dec; 47(12):1579-1584. PubMed ID: 34417396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study.
    Dover JS; Humphrey SD; Lorenc ZP; Shamban A; Gross TM; Rubio RG; Vitarella D
    Dermatol Surg; 2023 Jan; 49(1):60-65. PubMed ID: 36533798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines.
    Solish N; Kane MAC; Biesman BS; Brown J; Gallagher CJ
    Aesthet Surg J; 2023 Nov; 43(Suppl 1):S1-S9. PubMed ID: 36095026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.
    Humphrey S; Dover JS; Bowsher RR; Clancy A; Liu Y; Prawdzik G; Gallagher CJ
    Aesthet Surg J; 2023 Sep; 43(10):1189-1193. PubMed ID: 37051886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo.
    Carruthers J; Solish N; Humphrey S; Rosen N; Muhn C; Bertucci V; Swift A; Metelitsa A; Rubio RG; Waugh J; Quiring J; Shears G; Carruthers A
    Dermatol Surg; 2017 Nov; 43(11):1321-1331. PubMed ID: 28614091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OnabotulinumtoxinA treatment of moderate to severe glabellar lines in Chinese subjects after laser therapy: A prospective, open-label, noncomparative study.
    Wu Y; Lu Z; Xie Y; Zhang W; Chen X; Shi Y; Li Q; Halstead M; Rogers JD; Silberberg M
    J Cosmet Laser Ther; 2018 Oct; 20(5):278-286. PubMed ID: 29498553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
    Beer KR
    Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
    Grimes PE; Shabazz D
    Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.